<DOC>
	<DOCNO>NCT00683904</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose , dose-limiting toxicity , recommend Phase II dose ixabepilone combination carboplatin patient non-small cell lung cancer .</brief_summary>
	<brief_title>Ixabepilone Combination With Carboplatin Patients With Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Age ≥20 year Histologic cytologic diagnosis advance nonsmall cell lung cancer ( NSCLC ) Advanced NSCLC , define stage IIIB ( without indication radiotherapy ) , stage IV , recurrent No prior chemotherapycontaining regimen treatment NSCLC Eastern Cooperative Oncology Group performance status 01 Life expectancy least 12 week Accessible treatment follow ; patient could hospitalize first 15 day Cycle 1 Adequate recovery previous systemic therapy ( least 3 week surgery radiation therapy ) Women childbearing potential ( WOCBP ) unwilling unable use acceptable method avoid pregnancy study period 4 week last dose study drug Women pregnant breast feed Women positive pregnancy test result enrollment prior study drug administration Sexually active fertile men use effective birth control entire study period 3 month last dose study drug partner WOCBP Patients symptomatic require treatment brain metastasis and/or leptomeningeal metastasis Prior radiation must include ≥30 % major bonemarrowcontaining area ( pelvis , lumbar spine ) Common Terminology Criteria ( CTC ) Grade 2 great neuropathy Psychiatric disorder render patient incapable comply protocol requirement Any concurrent active malignancy nonmelanoma skin cancer carcinoma situ cervix ( Patients history malignancy without evidence disease 5 year eligible ) Serious uncontrolled medical disorder active systemic infection would impair ability subject receive protocol therapy . Myocardial infarction , unstable angina , unstable congestive heart failure within 6 month Known history infection human immunodeficiency virus Inadequate bone marrow function Inadequate hepatic function Inadequate renal function Known prior severe hypersensitivity reaction ( CTC Grade 2 great ) agent contain Cremophor®EL Known severe hypersensitivity reaction agent contain carboplatin platinum Prior treatment epothilone and/or platinum History highdose chemotherapy bone marrow transplant peripheral blood stem cell support within 2 year On treatment strong Cytochrome P450 3A4 inhibitor Current imprisonment Compulsorily detention treatment psychiatric physical illness</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>